NCT03392246View on ClinicalTrials.gov

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Osimertinib

"may stop (or inhibit) the growth of a cancer with a mutation in the EGFR gene"

DRUG

Selumetinib

"may enhance the effect of osimertinib to stop (or inhibit) the growth of a cancer with a mutation in the EGFR gene"

Trial Locations (4)

27710

Duke University, Durham

02214

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

lead

Dana-Farber Cancer Institute

OTHER